Biotech & AI drug discoveryNature Medicine

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial

The phase 2 UNICORN trial evaluated neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer. Trial results are not provided in the available context.

AI summary · generated only from source feed metadata; consult original

Source published2026-11-02T00:00:00+00:00

Published here2026-11-03T02:25:07+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04710-1

Original headline

Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.